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Abstract
Fabry disease (FD) is a rare, X-linked disorder caused by mutations in the GLA gene encoding 
the enzyme α-galactosidase A. Complete or partial deficiency in this enzyme leads to 
intracellular accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids 
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in many cell types throughout the body, including the kidney. Progressive accumulation of 
Gb3 in podocytes, endothelial cells, epithelial cells, and tubular cells contribute to the renal 
symptoms of FD, which manifest as proteinuria and reduced glomerular filtration rate leading 
to renal insufficiency. A correct diagnosis of FD, although challenging, has considerable 
implications regarding treatment, management, and counseling. The diagnosis may be 
confirmed by demonstrating the enzyme deficiency in males and by identifying the specific 
GLA gene mutation in male and female patients. Treatment with enzyme replacement therapy, 
as part of the therapeutic strategy to prevent complications of the disease, may be beneficial 
in stabilizing renal function or slowing its decline, particularly in the early stages of the disease. 
Emergent treatments for FD include the recently approved chaperone molecule migalastat 
for patients with amenable mutations. The objective of this report is to provide an updated 
overview on Fabry nephropathy, with a focus on the most relevant aspects of its epidemiology, 
diagnosis, pathophysiology, and treatment options.
IntroductionFabry disease (FD), also called Anderson-Fabry disease, is an X-linked lysosomal storage 
disorder causing defects in the glycosphingolipid metabolic pathway due to deficient or 
absent lysosomal α-galactosidase A (α-Gal A) activity. This results in the accumulation of 
globotriaosylceramide (Gb3) within lysosomes in a wide variety of cells, including endothelial, 
renal, cardiac, and dorsal root ganglion neuronal cells. The first descriptions of FD were made in 1898 by two physicians, William Anderson and Johannes Fabry, who described patients with ‘angiokeratoma corporis diffusum’ [1, 2], the red–purple maculopapular skin 
lesions that represent a characteristic feature of the disease. The prevalence of FD is now 
estimated to be between 0.85 and 2.5 cases per 100, 000 individuals worldwide [3], although 
it may be largely underestimated due to the wide spectrum of clinical phenotypes. This 
spectrum ranges from the “classic” severe phenotype in males to an apparent asymptomatic 
disease course occasionally observed in females, with a variety of clinical presentations in 
between depending on the residual α-Gal A activity, among other factors. The most common clinical features of FD include acroparesthesia and pain crisis, gastrointestinal disturbances, 
angiokeratomas and corneal dysfunction. If untreated, renal deposits, cardiomyopathy and/
or cerebrovascular disease lead to end-stage renal failure or cardiovascular events which 
may end in premature death, both in males and females [4, 5].
As FD is a progressive condition, a definitive diagnosis is crucial for patients having 
early access to optimal monitoring, supportive management, and appropriate treatment 
to prevent irreversible and life-threatening complications. In 2001, enzyme replacement 
therapy (ERT) for FD became available with the introduction of two products, agalsidase alfa 
(Replagal®, Shire HGT Inc) and agalsidase beta (Fabrazyme®, Genzyme Corp.). Agalsidase alfa and agalsidase beta are produced in different cell lines: agalsidase alfa is produced in a genetically engineered human cell line [6], whereas agalsidase beta is produced in a 
genetically modified CHO cell line [7]. Differences in the production process between 
agalsidase alfa and agalsidase beta lead to differences in their molecular structure [8-10]. 
Accordingly, agalsidase alfa and agalsidase beta have different optimal dosing regimens 
[6, 7]. The introduction of ERT provided the first opportunity to address the underlying 
enzyme deficiency, allowing the removal of part of the Gb3 deposits, improvement of Fabry-
related symptoms and (potential) protection of severely affected organs [11-13]. However, a 
considerable number of FD patients develop disease manifestations despite treatment [14]. 
It has been shown that ERT may slow or prevent irreversible damage in the cardiac and renal 
systems if started at an earlier stage, but it has lower efficacy in advanced cases [15-17]. In 
this report we provide an overview on Fabry nephropathy, a prominent feature of FD, with a 
particular focus on the most relevant aspects of its epidemiology, diagnosis, pathophysiology, 
and treatment options.
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Screening and prevalence of Fabry nephropathyFD screening among end-stage renal disease (ESRD) patients is an important clinical tool for the detection of FD patients, especially if it is followed by FD screening among family 
members of the index case, allowing genetic counseling and early therapeutic intervention 
[18]. Several studies have examined the prevalence of FD in high-risk populations such as 
patients with unexplained and overt left ventricular hypertrophy, premature strokes, or 
young ESRD patients [19]. A relevant study performed in Japan determined the frequency 
of unrecognized males with FD on chronic hemodialysis [20]. Six (1.2%) of 514 screened 
patients had low plasma α-Gal A activities and a missense mutation, and five of them 
presented as a novel “renal variant” phenotype, that was missing the classic symptoms of 
FD. Another Japanese study found one patient among 450 (0.22%) dialysis patients with the 
renal variant of FD [21]. Tanaka et al. [22] identified four male patients with low leukocyte 
α-Gal A and one female patient with low plasma α-Gal A among 696 hemodialysis patients 
(0.7% of the total population), highlighting that FD should be considered as the possible underlying etiology of unexplained ESRD not only in males but also in female patients 
undergoing hemodialysis.
In Austria, a cohort of 2480 patients (80.1% of the national dialysis population) was 
screened for the presence or absence of low α-Gal A activity by means of a blood spot 
test. Further workup included measurement of enzyme activity in leukocytes, followed by mutation testing of the GLA gene in subjects with low enzyme activity. FD was confirmed in 
four patients, resulting in a prevalence of 0.161% among dialysis patients [23]. The same 
blood spot screening method was used for detection of unrecognized Fabry patients among 
chronic dialysis patients in the Czech Republic [24]. A total of 117 out of 3370 patients (3.5%) 
tested positive (males 3.81%, females 3.19%). Based on consistently low α-Gal A activity in 
plasma and leucocytes, and the results of molecular analysis, five patients (4/1521 males, 
0.26%; 1/1849 females, 0.05%) could be newly diagnosed with FD. The same approaches 
have resulted in prevalences of 0.36% in the Southern Brazilian State [25], 0.23% in a Chinese 
population [26], 0.3–0.55% in Spain [27, 28], 0.17% in Turkey [29], and 0.02% in Japan [30].
Differences in the reported prevalence rates could be in part due to issues of laboratory 
methods and the choice of appropriate screening cutoff values. Most previous screening 
studies used a plasma α-Gal A assay as the initial test, whereas some used blood spots. 
However, several limitations of the plasma/blood spot enzyme assays have been identified: 
occurrence of false-negative [31] and false-positive results [32]; false-negative results are 
not prevented by use of inhibitors of α-galactosidase B activity [31]; and considerable intra-
individual variability in plasma α-galactosidase levels can reduce the discriminatory power 
of the screening test [31]. In addition, many females who are heterozygous for pathogenic 
GLA mutations have normal plasma α-Gal A activity, and up to one third of female Fabry 
patients are not identified by enzyme activity analysis [33]. Also, the results of these screening 
studies haveve to be taken with caution as some of the so-called “missense mutations” found 
in some patients are in fact DNA variants with unknown clinical significance.
Serum Gb3 level determined by tandem mass spectrometry has also been evaluated as a biomarker for screening of FD among dialysis-dependent patients, but it is associated with 
a high rate of false-positives [34]. In urine samples, elevated Gb3 levels are present at birth 
in male FD patients, suggesting a very early involvement of the kidneys in the disease [35]. A 
transversal study investigated potential predictors of urinary Gb3 excretion in patients with 
chronic kidney disease (CKD), evaluating total Gb3, Gb3-24 isoform, and Gb3-24:18 isoform 
ratio by direct electrospray ionization mass spectrometry. The Gb3-24:18 isoform ratio was 
not affected by potential influencing variables and FD was the sole condition associated with 
elevated Gb3-24:18 isoform ratio, rendering it a potent screening tool in unselected cohorts 
of CKD [36].
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With a different approach, Maruyama et al. [37] performed the first screening of dialysis 
patients for FD by measuring plasma Gb3 (lyso-Gb3), which has been shown to be clearly 
increased in the plasma of patients with symptomatic FD [38]. In this study, the plasma 
lyso-Gb3 screen identified FD with high sensitivity (100%) and specificity (94.3%), with a 
prevalence of FD in male dialysis patients of 0.07% [37].
In 2013, an Expert Consensus Document recommended to perform screening for FD 
in male CKD patients below 50 years of age in whom a reliable renal diagnosis is absent 
and in females with unexplained CKD, irrespective of age, with other unexplained symptoms 
potentially associated with FD. Recommendations for the screening methods were enzyme 
activity measurement for α-Gal A as a primary tool in males, followed by confirmation with 
mutation analysis when positive, and mutation analysis as a primary tool for screening 
in females [39]. However, in females with normal biochemical tests, it may be difficult to 
confirm or exclude the diagnosis of FD in the presence of a variant of unknown significance. 
Detection of the accumulating substance Gb3 in urine (rather than in plasma) could aid in 
detecting female heterozygotes and it can also be used in males as a surrogate marker to 
evaluate the response to ERT [40]. Plasma and urinary lyso-Gb3 may act as a biomarker/
diagnosing tool [41-43].
Biomarkers and diagnostic studies for Fabry nephropathy
As stated above, not all FD patients show the same clinical symptoms and, thus, diagnosis 
is often delayed, commonly for more than 15 years after the onset of the first manifestations 
[44]. Moreover, it has been reported that various drugs including amiodarone, chloroquine 
and hydroxychloroquine may mimic phospholipidosis of FD [45], so careful attention is 
required for the differential diagnosis of the disease. When classic skin and neurological features are absent, history of familial renal failure together with proteinuria may be 
suggestive of FD, and some specific mutations in the GLA gene, such as E66K, have been 
associated with preferential kidney involvement [46]. Of paramount importance is the 
detection of FD by family screening, as some relatives of an index case could be diagnosed 
at a younger age, before developing irreversible complications, and would benefit the most 
from the earlyinitiation of therapy [47]. It has been reported that for each index case, five 
additional immediate and extended family members, on average, can be diagnosed [48].
Several diagnostic approaches have been made, using different biomarkers and methods:1) Microalbuminuria/proteinuria. In routine clinical practice, proteinuria and microalbuminuria are considered the earliest signs of FD nephropathy [49], although many 
new markers, including Gb3 [50], cystatin C [51, 52] and bikunin [53], have been suggested 
to improve the estimation of renal function impairment.
2) Podocyturia. A recent case report indicated that podocyturia precedes the 
appearance of proteinuria, and could be considered an even earlier biomarker of kidney 
damage [54]. Tondel et al. [55] studied young Fabry patients with normal albuminuria and 
glomerular filtration rate (GFR) that underwent renal biopsies to characterize the degree 
of renal tissue damage prior to initiation of ERT. Significant Gb3 accumulation was found 
in several types of kidney cells with high amounts of Gb3 in the podocytes, without signs of 
clinical kidney disease. An important finding was the detection of early segmental podocyte foot process effacement in most normoalbuminuric young classic Fabry patients, highlighting 
the relevance of kidney biopsies for the early diagnosis of nephropathy.
3) Urine microscopy has demonstrated usefulness in diagnosing FD, as vacuolated 
epithelial cells, filled with glycosphingolipids, giving the appearance of a ‘Maltese cross’, can 
be seen using polarized light microscopy [56]. One report has suggested that screening for 
mulberry cells (regarded as distal tubular epithelial cells in which Gb3 has accumulated) 
during urinalysis could be a simple, inexpensive, and non-invasive method for diagnosing 
this Fabry nephropathy in the absence of proteinuria [57].
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4) Renal biopsy. A panel of nephrologists and international experts on FD indicated that 
a biopsy of the kidney with electron microscopy assessment is currently the only available 
tool that can reliably confirm or exclude FD nephropathy and should be considered in all patients without a classical pattern of disease manifestations, a GLA variant and CKD who 
have an uncertain diagnosis of FD [58]. This technique is also feasible for the routine study of 
paraffin-embedded kidney biopsies that have been immunostained with an anti-Gb3 antibody 
[59]. Of note, given that both the histological lesions (i.e. focal segmental glomerulosclerosis) 
and the clinical presentation (progressive proteinuria) are similar to that found in patients 
with either primary or secondary focal and segmental glomerulosclerosis (FSGS), an electron 
microscopy assessment should be performed in patients with unexplained FSGS [60]. A 
confirmatory study of α-Gal A activity should also be done to rule out Fabry nephropathy.
5) Proteomic analysis. An approach using urine proteomic analysis based on capillary 
electrophoresis coupled to mass spectrometry identified a distinct peptide profile in the 
urine that characterized adult female Fabry patients. The pattern was able to distinguish 
female Fabry patients from healthy controls and from patients with various other forms of kidney or systemic diseases [61]. In this regard, it is considered that urinary Gb3 levels in the high range, as usually seen in classical males, can differentiate between classical FD 
and other diseases. Moreover, the deacylated form of Gb3, lyso-Gb3, can clearly differentiate 
classical from non-classical FD patients [38, 62]. However, Schiffmann et al. [63] showed a 
lack of correlation between changes from baseline at month 12 in urine and plasma Gb3 
concentrations and renal outcomes, suggesting that changes in their levels do not predict 
clinical progression in FD.
Mechanisms of Fabry nephropathy: natural course and complications
Fabry nephropathy presents with a wide range of disease severity, both in males and 
females [64]; its overall rate of progression of CKD resembles that of diabetic nephropathy, 
and untreated patients frequently develop ESRD in their 50s [65], or even earlier [66]. 
Patients with Fabry nephropathy who develop kidney failure frequently suffer concurrent 
symptoms from other major organ systems [66].
Proteinuria is usually a manifestation of podocyte injury and urinary protein excretion 
is strongly associated with renal disease progression. Using data from 462 untreated adults 
(121 men and 341 women) who had at least two estimated GFR values over >12 months, 
Wanner et al. [67] found that patients with rapid progression had significantly higher mean 
averaged urinary protein to urinary creatinine ratios than patients with slower progression 
(1.5 vs 0.2 for men; 1.4 vs 0.5 for women; p<0.0001).  Other conditions, including 
hypertension, smoking, and hyperlipidemia, may also contribute to progressive loss of GFR 
in Fabry patients, as observed in other nephropathies [68]. Hypertension is not a common 
early ﬁnding in Fabry patients but becomes more prevalent with progression of the disease, 
and a signiﬁcant percentage of patients have blood pressure above the recommended values 
for patients with CKD [64].
Kidney biopsy provided important information that was not available from routine assessment of kidney function and proteinuria, highlighting the role of kidney biopsy in the 
baseline evaluation of all Fabry patients, even with mild clinical disease. Histologically, renal 
involvement results from glycolipid deposits in glomerular cells (particularly in podocytes and also in mesangial cells and endothelial cells), tubular epithelial cells (particularly of the distal nephron), and arterial and arteriolar endothelial, smooth muscle cells, and interstitial 
cells, which is associated with an early concentrating defect [69]. These features can be 
present in children at very early stages of the disease [70, 71]. Progression of kidney disease 
is characterized by proteinuria and irreversible ischemic changes in renal microvasculature 
that result in progressive glomerulosclerosis, capillary wall thickening, tubular atrophy, 
interstitial fibrosis, and arterial and arteriolar sclerosis. In one study, glomerulosclerosis 
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and tubulointerstitial fibrosis were predictors of proteinuria and CKD stage in female 
patients [72], whereas another study found sclerosing/fibrotic changes in renal biopsies 
of Fabry patients involving glomeruli (25% of the cases), interstitium (35% of the cases) 
and vessels (50 to 60%), with a negative correlation with renal function [73]. There has 
been an attempt to develop a standardized scoring system of both disease-specific lesions, 
i.e. lipid deposition related, and general lesions of progression, i.e. fibrosis and sclerosis, with the goal to determine whether baseline histologic information could be related to the 
rate of progression and/or response to ERT in Fabry nephropathy. The study showed that clinical disease was milder in the female cohort, with a corresponding lesser degree of global 
sclerosis and less podocyte, peritubular, vascular, and proximal tubule inclusions than in the 
males [74].
Some reports have documented the development of foot process effacement from 
podocyte injury in the absence of abnormalities in the urinalysis [75]. Podocytes are highly 
differentiated cells with a limited capacity for cell division and replacement, and podocyte 
injury and loss from the glomerulus results in ESRD by glomerular sclerosis [76]. There is 
evidence of progressive accumulation of podocyte Gb3 inclusions with increasing age in 
young Fabry patients with normal GFR and absent or low-grade proteinuria, with greater increases in foot process effacement in young male compared with female Fabry patients and 
normal subjects [77]. In cultured podocytes, lyso-Gb3, at concentrations found in the serum of Fabry patients, induced the production of mediators of podocyte injury, such as Notch1 
signaling, which represents a molecular pathway of potential pathogenic significance in 
Fabry nephropathy [78, 79]. Maurer et al. [80] showed a quantitative relationship in female 
Fabry patients between the X-inactivation phenomenon and podocyte injury manifesting as 
increased foot process effacement.
The assessment of renal function that should be carried out includes serum creatinine, 
cystatin C, estimates of GFR, total urinary protein excretion, (micro)albumin excretion, 
and urinary sodium excretion. The utility of urine protein/creatinine ratios and estimated 
GFR with the modification of diet with renal disease equation has been established [81]. 
Assessment of proteinuria and GFR can be used for the staging of CKD, as described in the 
Kidney Disease Outcomes Quality Initiative guidelines [82].
Treatment of Fabry nephropathy
Traditionally, treatment recommendations for Fabry nephropathy included controlling 
proteinuria to <0.5 g/day, controlling blood pressure and hyperlipidemia, and initiating ERT 
at the first sign of kidney involvement (or at the time of diagnosis for patients with little or 
no residual α-gal A activity) [83]. Those patients that develop kidney failure should undergo 
renal replacement therapy (dialysis or kidney transplantation).
The recommended therapeutic strategy for patients receiving ERT is to also receive 
angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) 
to reduce proteinuria [84]. The systematic use of antiproteinuric therapy with ACEIs and/
or ARBs was undertaken in a long-term open-label study of 10 patients [85]. They would 
historically have been at high risk for progressive loss of kidney function according to the 
phase III and phase IV results: baseline eGFR <60 mL/min/1.73 m2, and baseline urine 
protein excretion >1 g/day. When urine protein excretion was controlled to a target of ≤0.5 
g/day by carefully titrating ACEI and ARB doses in these adult Fabry patients who were 
also treated with agalsidase beta at 1 mg/kg every other week (EOW), the rate of loss of 
eGFR was not significantly different than zero [85]. A few years later, Warnock et al. [86] 
conducted a prospective observational study that examined the safety and efficacy of 
controlling proteinuria with ACEI or ARB therapy in FD patients who were receiving ERT 
with agalsidase beta. Results showed that proteinuria in most classical FD patients was 
controlled, but that kidney function was not preserved in patients who did not achieve the 
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urine protein to creatinine ratio (UPCR) treatment goal of 0.5 g/g. Kidney function was 
preserved in a minority of patients who started ERT at a younger age, and who maintained 
a UPCR < 0.5 g/g with antiproteinuric therapy [86]. There is some evidence supporting that 
the use of amiloride, a drug with proven effects in podocyte stabilization and proteinuria 
actions at the distal convoluted tubule, can decrease protein excretion in FD patients 
[87], but further research is needed. Another study evaluated the antiproteinuric effect of 
paricalcitol (PCT) in 15 FD patients with proteinuria >0.50 g/day persisting despite ERT 
and anti-renin–angiotensin system therapy titrated to maximum tolerated dosage [88]. Six 
months of add-on PCT signiﬁcantly decreased proteinuria to 0.4±0.3 g/day, with levels <0.50 
g/day achieved in four patients after 1 month, six after 3 months, and in 12 at 6 months, in 
the absence of changes to blood pressure and GFR. Interestingly, proteinuria recovered to 
basal values after PCT withdrawal [88].
As stated above, ERT could be provided by agalsidase alfa or agalsidase beta, by 
intravenous infusion at 0.2 mg/kg EOW and 1.0 mg/kg EOW, respectively. At this time, there 
is no robust evidence demonstrating superiority of either one in the treatment of FD [14, 
89]. The first reports of ERT efficacy on renal outcomes were encouraging [11, 90]; reversal 
of renal glycosphingolipid accumulation in the vasculature and in other renal cell types and 
decrease of Gb3 in podocytes and distal tubular epithelium were observed after 11 months 
of agalsidase alfa treatment [91]. From the large international database Fabry Outcome 
Survey (FOS), several studies have confirmed that treatment with agalsidase alfa stabilizes or 
minimizes eGFR decline in both male and female Fabry patients [92-95]. The study by Feriozzi 
et al. [93], in 165 patients followed for 3 years on treatment, also showed how proteinuria 
influences the loss of eGFR, with an average of 1.68 mL/min/1.73 m2/year in patients with 
baseline proteinuria <0.50 g/day (n = 40) and an average of 3.98 mL/min/1.73 m2/year in 
patients with values >0.50 g/ day (n = 14). These were confirmed by the same authors in 
a larger sample with a longer follow-up; in the whole cohort long-term ERT therapy was 
associated with a low decline in men and stabilization in women in the yearly reduction of 
eGFR (Fig. 1) [96]. In an analysis of pooled data from three randomized, placebo-controlled 
trials investigating the effect of ERT on renal function in a total of 108 adult male patients with 
FD, it was shown that measured GFR is stabilized for up to at least 4.5 years of treatment with 
agalsidase alfa [16]. A Brazilian study demonstrated that patients with mild (CKD stage 1) or 
moderate (CKD stage 3) renal impairment maintained stable GFRs over 3 years of treatment 
with agalsidase alfa. Only one patient (of 11), with stage 4 CKD, progressed to ESRD despite 
Fig. 1. Estimated GFR (eGFR) from baseline and throughout the follow-up in Fabry patients treated with 
agalsidase alfa. In parentheses: Numbers of patients in each group. Adapted from Feriozzi et al. (2012).
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continuing agalsidase alfa infusions, without evidence of improvement in proteinuria with 
ERT until kidney transplantation [97]. At the histological level, a significant correlation has 
been shown between the reduction in podocyte Gb3 inclusions and the cumulative dose of agalsidase alfa or beta in young, predominantly male patients (one female patient) treated 
for a mean of 60.3 months; irrespective of drug dosage, complete clearance of Gb3 inclusions 
was observed in the glomerular endothelial cells and mesangial cells in all patients after 
5 years of ERT [98]. Apart from the reported benefits of ERT on kidney function, several 
studies point to an action of this therapy against progression to cardiac and cerebrovascular 
complications [12, 94, 95, 99, 100]. In fact, risk of morbidity was reduced and survival was 
improved in treated patients from the FOS database compared to untreated groups from 
published literature [95]: median age at first composite event (renal, cardiac or stroke event, 
or death) was greater in agalsidase alfa–treated males and females, at 48 years and 56.9 
years, respectively, compared with untreated patients, at 41 years and 53 years, respectively, 
whereas the estimated median survival time was 77.5 years for male patients from FOS 
compared with 60 years in patients without ERT.
Different dosing regimens of agalsidase alfa have been rarely investigated. Increasing 
the frequency of dosing with agalsidase alfa from EOW to weekly in a subgroup of patients 
with FD whose eGFR continued to decline at rapid rate while being treated EOW significantly 
slowed the rate of decline in eGFR. Nine of 11 patients (82%) demonstrated either a positive 
eGFR slope (n = 3; 27%) or a slowing in their rate of decline (i.e., less negative eGFR slope; 
n = 6; 55%) after switching to weekly administration of agalsidase alfa. Only two patients 
had no improvement in their slope after switching from EOW to weekly dosing [101]. A 
randomized crossover study conducted by Hughes et al. [102] assessed the efficacy of three 
dosing schedules for FD (0.2 mg/kg EOW, 0.1 mg/kg weekly and 0.2 mg/kg weekly, each for 
4 weeks). Although the main analysis for pain and quality of life demonstrated no significant 
differences, there was a trend towards reduced urine Gb3 levels with weekly 0.2 mg/kg 
agalsidase alfa [102]. Comparing agalsidase alfa 0.2 mg/kg EOW with 0.2 mg/kg weekly 
over 1 year in treatment-naïve adults with FD, changes in eGFR were minimal and did not 
significantly differ between the two groups [103]. A global analysis by CKD stage showed 
that reductions in mean eGFR in patients with hyperfiltration (Stage 1A, ≥130 mL/min/1.73 m2) occurred by week 13 and remained stable until the end of the study, indicating possible 
normalization of renal function in these patients. The eGFR of patients with all other CKD stages was maintained throughout, thus indicating that renal function remained stable with 
either dosing regimen. Urine albumina/creatinine ratio also showed no significant changes 
at the end of the study [103].
Even in patients with ESRD undergoing dialysis, ERT, by addressing the underlying 
metabolic deficiency, may slow the progression or development of extra-renal signs and 
symptoms of the disease and improve quality of life [104]. In a nationwide cross-sectional 
survey study with prospective follow-up, 33 Italian Fabry patients with ESRD that had either 
undergone kidney transplantation or were on maintenance dialysis therapy received ERT for 
a minimum of 3 years. Signs of progression of cardiomyopathy in Fabry patients on dialysis 
were observed, while Fabry patients with a renal allograft generally had a stable cardiac 
condition and a rate of decline in allograft renal function below levels reported for untreated 
non-ESRD Fabry patients [105]. Cybulla et al. [106] examined the effects of agalsidase alfa in 20 transplant patients with Fabry disease in terms of allograft function after a median of 
~3.5 years of treatment. After 2 years of ERT, there was a non-significant increase in serum 
creatinine (1.4 mg/dL at baseline versus 1.6 mg/dL at 2 years) and a decrease in eGFR (59.2 
mL/min/1.73 m2 at baseline versus 51.1 mL/min/1.73 m2 at 2 years), whereas proteinuria 
remained stable during this time period [106].
The results of the Phase IV agalsidase beta (1 mg/kg) clinical trial in patients with mild 
chronic renal failure demonstrated the beneficial effects of agalsidase beta, as it may slow 
the progression of renal insufficiency, particularly if therapy is started when eGFR is still 
above 55 mL/min [12]. The Phase II agalsidase beta extension study showed that renal 
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function in the majority of patients remained stable, which was accompanied by reduction 
of plasma Gb3 and clearance in glomerular, tubular and interstitial endothelial cells and 
different renal cell types. However, renal disease progressed in some patients, which 
seemed to be related to the severity of the disease before treatment (most had significant 
proteinuria and evidence of sclerotic glomeruli) [107]. Thus, the initiation of ERT before 
the development of significant proteinuria is considered essential to prevent future kidney 
disease in these patients, as supported by a retrospective analysis of the progression of renal 
disease in patients not receiving ERT [65]. ERT initiated prior to CKD stage 5 was shown 
to be associated with stability in cardiac and renal disease while patients with CKD stage 
5 showed ongoing deterioration [108]. A 10-year observational study of 52 patients with 
classic FD investigated the effectiveness of agalsidase beta therapy (1mg/kg EOW) with 
regard to renal and other outcomes. Most patients remained alive and event-free, and mean 
plasma Gb3 normalized within 6 months. Mean slopes for eGFR were -1.89 mL/min/1.73 m2/
year and -6.82 mL/min/1.73 m2/year for starting ERT with less and greater kidney damage, 
respectively [17]. In line with these results, Warnock et al. [109] confirmed that the patients 
treated with agalsidase beta with the most stable renal function had lower mean average 
UPCR levels and higher mean baseline eGFR levels than those with the fastest renal disease 
progression. By contrast, in women with FD and mild renal involvement ERT was associated with stable renal function and a reduction in albuminuria as well as the decreased excretion 
of both glomerular and tubular protein markers [110]. A recent analysis of data from adult 
patients with FD enrolled in the Fabry Registry determined trends in the incidence of severe, 
potentially life-threatening clinical events (renal failure, cardiac events, stroke, death) over 
time in patients receiving up to 5 years’ treatment with agalsidase beta, at a dose of 1 mg/kg 
EOW [111]. The results showed that the incidence rate for severe clinical events decreased 
after the first 6 months of ERT; those patients at highest risk for severe clinical events, due 
to older age or male sex, displayed the greatest absolute reduction in event rate over time, 
and in particular had the greatest reduction in incidence rates for severe clinical events 
after the first 6 months of treatment [111]. Similarly, a single-center study of 57 ERT-treated 
patients observed that, in comparison to a historical group of untreated patients, the odds 
for development of a first severe clinical event declined with longer treatment duration 
per year of ERT (odds ratio 0.81, 95% confidence interval 0.68 to 0.96) [100]. However, a 
cost-effectiveness study of ERT compared with standard medical care in a Dutch cohort of 
patients with FD concluded that in symptomatic patients, ERT has limited effect on quality 
of life and progression to end-organ damage, and this modest effectiveness drives the costs 
per quality of adjusted life years and the costs per year free of end-organ damage to millions 
of euros [112].
As part of the therapeutic strategies for FD, pharmacological chaperones have shown 
great promise for patients with specific mutations resulting in misfolded or unstable 
enzymes and, among them, migalastat has recently been approved for the treatment of FD 
[113]. Migalastat hydrochloride is an analog of the terminal galactose of Gb3 that binds and 
stabilizes wild type and mutant forms of α-Gal A [114]. In a phase III trial of migalastat a 
significant and durable reduction in kidney Gb3 levels was seen in migalastat treated patients 
with amenable mutations [115]. Additionally, the annualized rates of change in eGFR among 
this group decreased less than the eGFR of historic untreated patients [65, 67], regardless 
of the baseline levels of urinary protein excretion. Other benefits of this agent include being 
non-invasive because it is taken orally, exhibiting broad tissue distribution [116], and gaining 
access to the central nervous system [117]. However, as a genotype-specific therapy it is 
estimated that only one-third of mutations may be amenable to migalastat.
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Conclusion
During the last decades, we have gained great knowledge about FD pathophysiology, 
natural course, and treatment, but many patients still receive the correct diagnosis rather 
late in the course of the disorder. Hence, it is essential to raise awareness of this disease in 
the general population and among physicians, as a definitive diagnosis in these cases has 
the potential to improve medical care in the affected individual, as well as perhaps leading 
to identification of the disease in relatives. All males who are hemizygous for FD can be 
diagnosed by demonstrating a deficiency of α-Gal A activity in plasma and/or leukocytes, but the mutation in the GLA gene should be also determined. Heterozygous females cannot 
be diagnosed reliably by enzymatic assay because α-Gal A activity in plasma varies according 
to inactivation of the X chromosome, so mutation analysis is the primary tool for screening 
in females.
Multiple studies have shown that the renal manifestations of FD occur early in life 
in a significant proportion of children, in many women, and in almost all men with this 
disorder. These manifestations progress to ESRD in nearly all males and some female 
patients. Proteinuria, as a manifestation of podocyte injury in Fabry nephropathy, is strongly 
associated with renal disease progression.
ERT with agalsidase alfa or agalsidase beta has become the major approach to the 
treatment of patients with FD. ERT slows or prevents irreversible damage in the cardiac 
and renal systems if started at an earlier stage, but it has lower efficacy in advanced 
stages. Adjunctive therapy from management of CKD and cardiovascular risk factors is 
also mandatory. Migalastat has recently been approved for the treatment of FD, with the 
advantages of its oral administration and broad tissue distribution. The ultimate goal of ERT 
and other therapies should be the avoidance of severe complications. In general, prevention 
is likely to be more effective than attempting to reverse already damaged organs in FD 
patients.
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